Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Ingrezza (valbenazine) is prescription medication for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease.
Ingrezza 40 mg, 60 mg, and 80 mg oral capsules and Sprinkle capsules may be dispensed with a valid prescription.
Fact Table | |
Formula | C24H38N2O4 |
License | US FDA |
Bioavailability | 49% |
Legal status | Prescription only (Rx) |
Chemical Name | Valbenazine |
Elimination half-life | 20 hours (Valbenazine), 32-38 hours (Active metabolite) |
Dosage (Strength) | 40 mg, 80 mg capsules |
Pregnancy | Consult a doctor |
Brands | Ingrezza |
Protein binding | 99% |
PubChem CID | 54736335 |
MedlinePlus | a617008 |
ChEBI | 134730 |
ATC code | N07XX11 |
DrugBank | DB11809 |
KEGG | D10913 |
Routes of administration | Oral |
Ingrezza should be taken as prescribed by your doctor, who will decide on an appropriate dosage for you.
Keep Ingrezza capsules stored between 15°C and 30°C (59°F and 86°F).
Keep Ingrezza Sprinkle stored between 20°C and 25°C (68°F and 77°F).
Keep medications out of children’s reach.
Consult the medication guide included with your Ingrezza prescription for additional usage instructions.
Tell your doctor or pharmacist about any questions or concerns you have.
Valbenazine is the active ingredient in Ingrezza.
Hypromellose, isomalt, magnesium stearate, pregelatinized starch, silicified microcrystalline cellulose, candurin silver fine, FD&C Blue#1, FD&C Red#40, and gelatin are the inactive ingredients in Ingrezza capsules.
Silicified microcrystalline cellulose, isomalt, pregelatinized maize starch, hypromellose, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, gelatin, and candurin silver fine are the inactive ingredients in Ingrezza Sprinkle.
Ingrezza should not be administered to patients who are allergic to valbenazine or to any of the other ingredients in Ingrezza.
The most common side effect of Ingrezza in patients with tardive dyskinesia is excessive sleepiness.
The most common side effects of Ingrezza in patients with chorea associated with Huntington’s disease include excessive sleepiness, lethargy, sedation, hives, rash, and trouble sleeping.
Other side effects may also occur, so immediately call your doctor if you have bothersome or persistent side effects.
Looking for an Ingrezza price that’s competitive? Here, you can buy Ingrezza with a valid prescription from your doctor!
Ingrezza. San Diego, CA: Neurocrine Biosciences, Inc.; 2024